Retatrutide has emerged as a new treatment in the fight against obesity. This groundbreaking drug, belonging to a dual GLP-1 and GIP receptor agonist, shows promising results in clinical trials. By activating these receptors, Retatrutide controls cravings, {promotesglucose regulation, and ultimately leads to significant slimming. While research is